skip to Main Content

By: Crystal Carter, Texas A&M Innovation

Texas A&M startup Sano Chemicals has announced the successful completion of its Phase 1 human clinical trial for Occidiofungin, the first-in-class antifungal agent designed to treat recurrent vulvovaginal candidiasis (RVVC), commonly known as recurrent vaginal yeast infections. The company is now seeking investors to propel Occidiofungin into the next phase of development. This groundbreaking development marks a significant step forward in addressing an unmet medical need affecting millions of women worldwide.

Scientific Roots at Texas A&M University
Occidiofungin’s discovery is rooted in academic collaboration. Dr. James Smith, a Texas A&M University biology professor, began research on this antifungal compound nearly 15 years ago alongside Dr. Shien Lu and Dr. Frank Austin, professors at Mississippi State University. Their pioneering work led to the formation of Sano Chemicals; a company dedicated to leveraging innovative science for public health breakthroughs.

Dr. Smith, now serving as Sano Chemicals’ Co-CEO, Founder, and Chairman of the Board of Directors, brings personal passion to the fight against infectious diseases. Wheelchair-bound since the age of 18 due to an infectious disease, Smith remarked, “I know firsthand the life-altering impact of infectious diseases, which fuels my commitment to developing solutions like Occidiofungin.”

RVVC impacts approximately 9 million women annually in the U.S. and 130 million globally, causing symptoms that disrupt daily life. Despite its prevalence, effective treatments for RVVC have been lacking. Occidiofungin, marketed as the Fungus Killer™, is positioned to fill this gap. The intravaginal gel directly targets yeast infections without disrupting the beneficial organisms critical to vaginal health. Unlike existing therapies, Occidiofungin bypasses reliance on the immune system, killing the yeast rapidly and efficiently at the infection site.

The Phase 1 clinical trial, conducted in December 2024, demonstrated that Occidiofungin is safe and well-tolerated among the 24 participants aged 19-45. No significant adverse effects or changes in vital signs, gynecological exams, or other health indicators were reported. Participants found the medication easy to use and free of discomfort.

Excitement and the Road Ahead
Dr. Janice Miles, Co-CEO of Woman’s Health at Sano Chemicals, expressed optimism about the breakthrough. “We are excited about the science and what it can do,” she said. “Occidiofungin has the potential to dramatically improve the lives of millions of women suffering from this condition.”

Sano Chemicals is now seeking investors to propel Occidiofungin into the next phase of development. Stock sales will commence the week of January 10, 2025, via StartEngine, providing an opportunity for stakeholders to support this revolutionary antifungal therapy.

With its Qualified Infectious Disease Product and Fast Track designations from the FDA, Occidiofungin offers hope to millions worldwide. As Sano Chemicals continues to innovate, this novel therapy has the potential to reshape the landscape of antifungal treatments.

Back To Top